BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26166037)

  • 1. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
    Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
    Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
    Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
    Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 10. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
    Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
    Zhang B; Jiao J; Liu Y; Guo LX; Zhou B; Li GQ; Yao ZJ; Zhou GB
    PLoS One; 2012; 7(11):e48748. PubMed ID: 23185274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
    Xie YJ; Gao WN; Wu QB; Yao XJ; Jiang ZB; Wang YW; Wang WJ; Li W; Hussain S; Liu L; Leung EL; Fan XX
    Pharmacol Res; 2020 Sep; 159():104934. PubMed ID: 32464330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer.
    Yang Q; Chen W; Xu Y; Lv X; Zhang M; Jiang H
    Toxicol Appl Pharmacol; 2018 Oct; 356():1-7. PubMed ID: 30076870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
    Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
    Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.